2000-194082/17 B05 VEKT= 1996.04.19 B(1-D2, 3-F, 3-H, 4-H5AE, 5-B1P, 7-A2, 14-A2) .7 \*RU 2123328-C1 VEKTOR RES CENTRE 1996.04.19 1996-108008(+1996RU-108008) (1998.12.20) A61K 9/127, 38/21 (9999DwgNo.0/0) Liposomal antiviral drug for oral using C2000-060059 Addnl. Data: ZOLIN V V, KOLOKOLTSOV A A, BARANOV YU N **NOVELTY** Invention proposes a drug for treatment of patients with viral infections. An agent is a lyophilizate or isotonic solution. Lyophilizate has the following components: recombinant interferon-alpha-2 (2.5-10) x 10 IU and also, mg: phosphatidylcholine 60-80; cholesterol 6-10; alpha-tocopherol 6-10; ascorbic acid 1-2, and sucrose 40-90. An agent is stable in gastroenteric tract and absorbed in proximal part of small intestine. Agent is stable and does not hydrolyzed during absorption and has no show adverse effects. **USE** Medicine, virology.

<u>ADVANTAGE</u>

Enhanced therapeutic effectiveness at oral intake. 1 tbl, 8 exa

RU 2123328-C